Enbrel(R) (etanercept) Data to be Presented at the 2009 American College of Rheumatology Scientif...( THOUSAND OAKS Calif. and COLLEGEVILLE...),Health

THOUSAND OAKS, Calif. and COLLEGEVILLE, Pa., Oct. 16 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) and Pfizer (NYSE: PFE), today announced new scientific data about ENBREL being presented at the 2009 American College of Rheumatology (ACR) Scientific Meeting in Philadelphia, Pa., from Oct. 17-21, 2009. These presentations contribute to data generated through 17 years of collective clinical experience.

"The clinical data being presented at ACR expand on the breadth of rheumatologists' knowledge and contribute to the continued understanding of treating the rheumatic conditions for which ENBREL is approved in the U.S.," said Sean Harper, M.D., senior vice president and chief medical officer, Amgen. "New data from an established therapy such as ENBREL continue to inform the medical and scientific community with the goal of advancing patient care."

These studies include a broad range of patients with moderate to severe rheumatoid arthritis and psoriatic arthritis. See Indications and Important Safety Information below.

A comprehensive list of ACR abstracts is available online at http://acr.confex.com/acr/2009/schedule/index.cgi. Identified below are some abstracts of interest on ENBREL data.

    -- Sustainability of Clinical Remission with Etanercept and Methotrexate,
       in Combination or as Monotherapy, in Early Active Rheumatoid Arthritis
       Lead author:  Emery, P.
       Abstract No. 1656 (Tuesday, Oct. 20, 2009)
    -- Etanercept Benefits Skin, Joint, and Entheseal Symptoms in Patients
       with Psoriasis and Psoriatic Arthritis: The PRESTA Trial
       Lead author:  Kirkham, B.
       Abstract No. 523 (Sunday,
'/>"/>
SOURCE  Amgen
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 
Related medicine news :

1. Enbrel(R) (etanercept) Is the First Biologic With Published Efficacy and Safety Data for up to a Decade of Continuous Use for the Treatment of Moderate to Severe Rheumatoid Arthritis
2. Plastic Surgery 2009 News Briefs - Selected Research to be Presented on Tuesday, October 27
3. Plastic Surgery 2009 News Briefs - Selected Research to be Presented on Monday, October 26
4. Plastic Surgery 2009 News Briefs - Select Research to be Presented on Sunday, October 25
5. Plastic Surgery 2009 News Briefs -- Research To Be Presented on Saturday, October 24
6. Novel Information about Vulnerable Coronary Artery Plaque to be Presented at Transcatheter Cardiovascular Therapeutics (TCT) 2009
7. PolyOne Presented with Frost & Sullivan Medical Product Award
8. CRF announces featured clinical trials to be presented at TCT 2009 in San Francisco
9. Kuvan and Naglazyme Data to Be Presented at the 11th Annual ICIEM Meeting
10. Centers of Excellence Awards Presented to Over 100 Nursing Facilities as Nursing Facilities Reach the Tipping Point in Treating Pressure Ulcers
11. CRF announces late breaking trials to be presented at TCT 2009 in San Francisco